| Publication Information (EuropePMC) | |
| Title | Genetic liability to psoriasis predicts severe disease outcomes. |
| PubMed ID | 41408349(Europe PMC) |
| doi | 10.1186/s13073-025-01561-2 |
| Publication Date | Dec. 17, 2025 |
| Journal | Genome Med |
| Author(s) | Saklatvala JR, Lessard S, Teder-Laving M, Thomas LF, Ramessur R, Zierer J, Åsvold BO, Barton A, Baudry D, Bowes J, Brumpton B, Bruno S, Chandran V, Chatelain C, de Rinaldis E, Elder JT, Ellinghaus D, Foerster J, Franke A, Gladman DD, Gulliver W, Hüffmeier U, Huilaja L, Hveem K, Khader S, Kingo K, Klinger K, Kolbinger F, Kõks S, Liao W, Nair RP, Nititham J, Rahman P, Reis A, Sagoo MK, Stuart PE, Tasanen K, Traks T, Tsoi LC, Uebe S, Watts K, BSTOP study group, Barker JN, Mahil SK, Langan SM, FinnGen, Estonian Biobank research team, Brown SJ, Løset M, Paternoster L, Dand N, Smith CH, Simpson MA. |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS005308 (GWS-noHLA) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 64 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005308/ScoringFiles/PGS005308.txt.gz |
| PGS005310 (Full-noHLA) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 513,460 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005310/ScoringFiles/PGS005310.txt.gz |
| PGS005307 (GWS) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 64 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005307/ScoringFiles/PGS005307.txt.gz |
| PGS005311 (Full_subset) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 487,311 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005311/ScoringFiles/PGS005311.txt.gz |
| PGS005312 (Full-noHLA_subset) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 487,310 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005312/ScoringFiles/PGS005312.txt.gz |
| PGS005309 (Full) |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Psoriasis | psoriasis | 513,461 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005309/ScoringFiles/PGS005309.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM023015 | PGS005307 (GWS) |
PSS012098| European Ancestry| 9,426 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.19 [1.12, 1.26] | — | — | — | — |
| PPM023016 | PGS005308 (GWS-noHLA) |
PSS012098| European Ancestry| 9,426 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.22 [1.15, 1.3] | — | — | — | — |
| PPM023017 | PGS005309 (Full) |
PSS012098| European Ancestry| 9,426 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.33 [1.25, 1.41] | — | — | — | — |
| PPM023018 | PGS005310 (Full-noHLA) |
PSS012098| European Ancestry| 9,426 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.4 [1.32, 1.49] | — | — | — | — |
| PPM023019 | PGS005307 (GWS) |
PSS012094| European Ancestry| 14,167 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.44 [1.36, 1.51] | — | — | — | — |
| PPM023020 | PGS005308 (GWS-noHLA) |
PSS012094| European Ancestry| 14,167 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.25 [1.18, 1.31] | — | — | — | — |
| PPM023021 | PGS005309 (Full) |
PSS012094| European Ancestry| 14,167 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.49 [1.41, 1.57] | — | — | — | — |
| PPM023022 | PGS005310 (Full-noHLA) |
PSS012094| European Ancestry| 14,167 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.38 [1.31, 1.45] | — | — | — | — |
| PPM023023 | PGS005307 (GWS) |
PSS012096| European Ancestry| 8,603 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.26 [1.19, 1.33] | — | — | — | — |
| PPM023024 | PGS005308 (GWS-noHLA) |
PSS012096| European Ancestry| 8,603 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.23 [1.17, 1.31] | — | — | — | — |
| PPM023025 | PGS005309 (Full) |
PSS012096| European Ancestry| 8,603 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.29 [1.22, 1.36] | — | — | — | — |
| PPM023026 | PGS005310 (Full-noHLA) |
PSS012096| European Ancestry| 8,603 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.25 [1.19, 1.33] | — | — | — | — |
| PPM023027 | PGS005307 (GWS) |
PSS012095| European Ancestry| 12,708 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.22 [1.17, 1.26] | — | — | — | — |
| PPM023028 | PGS005308 (GWS-noHLA) |
PSS012095| European Ancestry| 12,708 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.19 [1.15, 1.24] | — | — | — | — |
| PPM023029 | PGS005309 (Full) |
PSS012095| European Ancestry| 12,708 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.23 [1.18, 1.27] | — | — | — | — |
| PPM023030 | PGS005310 (Full-noHLA) |
PSS012095| European Ancestry| 12,708 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis | OR: 1.23 [1.18, 1.28] | — | — | — | — |
| PPM023031 | PGS005311 (Full_subset) |
PSS012093| European Ancestry| 13,577 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (BSTOP) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 15.3 | — | — |
| PPM023032 | PGS005312 (Full-noHLA_subset) |
PSS012093| European Ancestry| 13,577 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (BSTOP) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 15.3 | — | — |
| PPM023033 | PGS005311 (Full_subset) |
PSS012097| European Ancestry| 10,887 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (Novartis) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 11.6 | — | — |
| PPM023034 | PGS005312 (Full-noHLA_subset) |
PSS012097| European Ancestry| 10,887 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (Novartis) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 11.5 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012093 | — | — | 4,151 individuals | — | European | — | BSTOP | 4,151 in BSTOP is compared against 9426 UKB |
| PSS012093 | — | — | 9,426 individuals | — | European | — | UKB | 4,151 in BSTOP is compared against 9426 UKB |
| PSS012094 | — | — | [
|
— | European (Estonian) |
— | EB | — |
| PSS012095 | — | — | [
|
— | European (Finnish) |
— | FinnGen | — |
| PSS012096 | — | — | [
|
— | European (Norwegian) |
— | HUNT | — |
| PSS012097 | — | — | 1,461 individuals | — | European | — | Novartis | 1,461 in Novartis is compared against 9426 UKB |
| PSS012097 | — | — | 9,426 individuals | — | European | — | UKB | 1,461 in Novartis is compared against 9426 UKB |
| PSS012098 | — | — | [
|
— | European (British) |
— | UKB | — |